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Background: Glioblastoma multiforme (GBM) is one of the most aggressive forms of cancer with a high rate of
recurrence. We propose a novel oncolytic vaccinia virus (VACV)-based therapy using expression of the bone
morphogenetic protein (BMP)-4 for treating GBM and preventing recurrence.
Methods: We have utilized clinically relevant, orthotopic xenograft models of GBM based on tumor-biopsy derived,
primary cancer stem cell (CSC) lines. One of the cell lines, after being transduced with a cDNA encoding firefly
luciferase, could be used for real time tumor imaging. A VACV that expresses BMP-4 was constructed and utilized
for infecting several primary glioma cultures besides conventional serum-grown glioma cell lines. This virus was also
delivered intracranially upon implantation of the GBM CSCs in mice to determine effects on tumor growth.
Results: We found that the VACV that overexpresses BMP-4 demonstrated heightened replication and cytotoxic
activity in GBM CSC cultures with a broad spectrum of activity across several different patient-biopsy cultures.
Intracranial inoculation of mice with this virus resulted in a tumor size equal to or below that at the time of
injection. This resulted in survival of 100% of the treated mice up to 84 days post inoculation, significantly superior
to that of a VACV lacking BMP-4 expression. When mice with a higher tumor burden were injected with the VACV
lacking BMP-4, 80% of the mice showed tumor recurrence. In contrast, no recurrence was seen when mice were
injected with the VACV expressing BMP-4, possibly due to induction of differentiation in the CSC population and
subsequently serving as a better host for VACV infection and oncolysis. This lack of recurrence resulted in superior
survival in the BMP-4 VACV treated group.
Conclusions: Based on these findings we propose a novel VACV therapy for treating GBM, which would allow
tumor specific production of drugs in the future in combination with BMPs which would simultaneously control
tumor maintenance and facilitate CSC differentiation, respectively, thereby causing sustained tumor regression
without recurrence.
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The emergence of a cancer stem cell (CSC) concept has
if not revolutionized but certainly altered views about
the origin(s) of cancer and what the new anti cancer mo-
dalities should target. The main properties of CSCs as
identified by a distinguished group of CSC scientists after
the AACR workshop in 2006 [1] are the ability to initiate
and maintain a tumor including the CSC compartment
(self renewal) and generation of differentiated progeny
that make up the bulk of the tumor. This makes the CSC
at the apex of neoplastic transformation where its unique
stem cell properties of self renewal and multipotency
enables it to initiate, fuel and sustain tumor growth. The
original study by John Dick and colleagues that used im-
munodeficient mice to xenograft tumorous cells was a
seminal study [2]. These researchers found that most sub-
types of acute myeloid leukemia could be implanted in
these mice, but found heterogeneity within these tumors.
Only one in a million tumor cells could initiate tumors,
thereby this capability lying in only a subset of tumorous
cells. In case of solid tumors, the ground breaking work
was carried out by Clarke and coworkers in 2003 [3]. They
established the tumor initiating capability to reside in a
subset of cells in breast tumors. This was followed by
identification of CSCs in brain tumors [4,5]. Very inter-
estingly it was demonstrated that the GBM CSCs are
multipotent and could be maintained as spheroids in vitro
almost indefinitely without significant change in proper-
ties [4]. CSCs have also been identified now in colon
cancer, pancreatic cancer, liver cancer, ovarian cancer,
melanoma and thyroid cancer [6-12].
Initial efforts for targeting CSCs involved targeting path-
ways that are involved in development that are thought to
be active in undifferentiated and primitive cells, namely
the Wnt-beta catenin, Notch and the Hedgehog path-
ways [13-15]. Limited success has been achieved targeting
these pathways using small and large molecule inhibitors
[16-18]. Another class of therapeutics entails the use of
recombinant proteins that are being designed exclusively
to target the undifferentiated cell population component
in tumors ([19,20]. Prominent among this class has been
recombinant proteins belonging to the TGF-beta super-
family of proteins called bone morphogenetic proteins
(BMPs). BMPs are involved in embryonic development,
organ morphogenesis and adult tissue homeostasis [21,22].
There is direct and indirect evidence for a role of BMPs
in regulating cancer. Mutations in the BMP receptor or
Smad4, a key mediator of BMP signal transduction pre-
disposes patients to colorectal cancer [23,24]. It is also
documented that upregulation of inhibitors of BMPs,
such as Coco and Gremlin result in activation of breast
cancer metastases [25] and occurrence of lung adeno-
carcinoma [26], respectively. In the context of gliomas,
BMP-4 expression was found to correlate well with lowergrade gliomas and better prognosis in grade III and grade
IV gliomas (GBM) [27]. BMPs have also been shown to
inhibit breast CSCs and the tumorigenicity of an osteo-
sarcoma cell line [28,29]. Practical application of BMPs
and their ability to negatively regulate cancer has come
from the work of Piccirillo, et al., where they have shown
BMPs can cause rapid tumor regression in case of GBM
[19] and made a case for use of BMPs in the treatment
of the disease. More recently BMP-4 has been used as a
differentiation agent in controlling colon cancer in mice
[30] using models based on CSCs.
There are few literature reports of studies involving
CSCs and infections by oncolytic poxviruses. Vaccinia virus,
a member of the family poxviridae has been found to not
infect all primary hematolymphoid cells [31,32]. Therefore,
there could be a tropism issue associated with infection
of primary cells by vaccinia virus that could be accentu-
ated upon using attenuated mutants used for oncolytic
therapy. However, some other poxviruses, such as myx-
oma virus has been shown to readily infect primary neuro-
blastoma CSCs. Therefore, it has been of interest to test
oncolytic vaccinia viruses against bonafide CSC prepara-
tions to determine susceptibility to infection. We had hy-
pothesized that expressing payloads such as BMPs from
oncolytic vaccinia viruses would facilitate delivery of the
proteins to expedite differentiation of previously validated
CSCs that produce GBM in an authentic manner [4]. In-
deed, here we report, that BMP-4 expressing vaccinia
viruses produce the protein in primary GBM cultures and
in the brains of GBM CSCs-transplanted mice, differentiate
GBM CSCs and further increase replication capacity of the
virus resulting in substantial tumor regression and survival
benefit to mice implanted with the GBM CSCs.
Methods
Cell culture
The primary GBM CSC cultures were derived from tumor
biopsies and labeled based on the day the biopsy was
obtained, with the first two digits standing for the year,
the next two for the month and the last two for the day.
These cultures were propagated under serum-free condi-
tions as described previously [4]. Briefly, these cultures
were propagated in Neurocult NS-A medium (Stem Cell)
in the presence of EGF and b-FGF (NSC medium) [4].
U87, U373 and U251 glioma lines were obtained from the
ATCC. They were grown based on the recommendations
of the supplier. In order to adapt the glioma cell lines to
stem cell conditions, the cell lines were passaged under
conditions as described above and a suffix “s” added after
name of each cell line. All cell lines were authenticated by
morphology and growth characteristics. To create a firefly
luciferase (FLuc) expressing U87 cell line, U87 cells were
transfected with a plasmid that expresses the FLuc cDNA
(pGL4.51[luc2/CMV/Neo], Promega) using Lipofectamine
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500 μg/mL G418 sulfate (Mediatech).Construction of recombinant VACV strains expressing BMP-4
A cDNA encoding the human BMP-4 was PCR ampli-
fied using Human Universal cDNA mix (Clontech) as
the template with primers BMP-4-5 (5’-GTCGAC(Sal I)
CACCATGATTCCTGGT AACCGAATGCTGATGG -3’)
and BMP-4-3 (5’-TTAATTAA(Pac I) TCAGCGGCACCC
ACATCC -3’). The PCR product was gel-purified and
cloned into the pCR-Blunt II-TOPO vector using Zero
Blunt TOPO PCR Cloning Kit (Invitrogen). The sequence
of BMP-4 cDNA was confirmed and was released with
Sal I and Pac I digestion and subcloned into the vaccinia
TK transfer vectors cut with the same restriction enzymes,
placing the BMP-4 cDNA under the control of the early/
late VACV promoter. The resulting constructs were used
to make recombinant virus, GLV-1h285 using GLV-1h189
as the parental virus as previously described [33]. BMP-4
expression from GLV-1h285 was confirmed by western
blot analyses where both the secreted and precursor forms
were detected upon infecting GBM CSCs and CV-1 cells
(data not shown).Cell growth inhibition and virus replication assays
Cell growth inhibition assays were carried out in 96 well
black plates (Costar). Eight serial virus dilutions (1:3) were
carried out to keep the concentration twice that of the
final concentration. A 100 μL sample of each cell line
(1.7 × 105 cells/mL) was mixed with 100 μL of each virus
dilution and 30 μL of this was plated in triplicate for
each cell line. Virus adsorption was carried out at 37°C
for an hour and then the volume was brought up to
150 μL with NSC medium. At day 9, plates were developed
using the Cell titer glo (CTG) kit (Promega) and read with
a SpectraMax M5 plate reader (Molecular Dynamics). The
effective concentration (EC50) values were calculated as the
virus multiplicity of infection (MOI) at which 50% growth
inhibition was achieved.
Replication assays were carried out as the growth in-
hibition assays except that the Renilla luciferase (RLuc)
glo kit (Promega) was employed. To determine that
BMP-4 increased replication of GLV-1h285, GBM CSC
line 010627 was infected with GLV-1h189 in the pres-
ence of 100 ng/mL of purified BMP-4 (R&D Systems)
and replication was measured by RLuc expression at day
9 post infection (dpi). For determining viral titers, GBM
CSC line, 010627 and U87s were infected at an MOI of
0.25 with both GLV-1h189 and GLV-1h285. Cultures
were collected 9 dpi and subjected to 3 freeze-thaw cy-
cles. Virus plaque assays were carried out as previously
described [34].Immunofluorescence staining
Cells of GBM CSC line, 010627 line were seeded on
laminin (Roche) coated 24 well plates and treated with
100 ng/mL BMP-4 (R&D systems) or were infected with
viruses at an MOI of 1. After 4 days samples were fixed
in 4% methanol-free paraformaldehyde in PBS and perme-
abilized with 0.25% Triton X-100. To block nonspecific
binding of the antibodies cells were incubated with 1%
BSA in PBS Triton X-100 (PBST) for 30 minutes. Cells
were incubated with primary antibody against glial fi-
brillary acidic protein (GFAP, Dako Cytomation) diluted
1:500 in 1% BSA in PBST in a humidified chamber for
1 hour at room temperature. The secondary antibody
(Alexa Fluor® 350 goat anti-rabbit IgG, Invitrogen) was
diluted 1:500 in 1% BSA and incubated for 1 hour at room
temperature in the dark. The plates were observed under
a fluorescence microscope (Carl Zeiss) and photographed.
Intracranial tumor cell implantation and inoculation of virus
Animal studies were performed in accordance with animal
welfare regulations approved by the Institutional Animal
Care and Use Committee of Explora Biolabs.
Five to six week old male Hsd:athymic Nude-Foxn1nu
mice (Harlan) were anesthetized by intra-peritoneal in-
jection of a ketamine (100 mg/kg), dexmedetomidine
(0.25 mg/kg) and buprenorphine (0.08 mg/kg) cocktail
and immobilized in a stereotactic apparatus (Kopf Instru-
ments). Tumor cells (2.5 × 105 cells of GBM CSC line,
010627 expressing FLuc, or U87 FLuc cells in 2 μL cell
culture medium) were implanted over a 5-minute period
at 2.5 mm medial lateral and 2.5 mm dorsoventral relative
to bregma zero coordinates using a micro-drill (Ideal
Micro-Drill™) and a Hamilton syringe. The incision was
closed with Ethicon 4–0 sutures and tissue adhesive.
Anesthesia was reversed with an intra-peritoneal injec-
tion of altipamezole (0.1 mg/kg). Virus treatment was
started 2–7 weeks after tumor cell implantation by a sin-
gle intra-cranial injection (2.5 × 106 pfu in 2 μL PBS). Five
mice per group were used in the low tumor burden study
and nine mice per group were used in the high tumor
burden study.
Luminescence imaging of tumor growth
Nude mice bearing FLuc expressing tumor cells were
imaged after being injected intraperitoneally with 120 μL
of a 30 mg/mL D-luciferin solution (GoldBio) using an
animal imager (Bruker). Quantitation of luciferase signal
was carried out using the Molecular Imaging software
(Bruker). To determine the trend of tumor growth over
time, median tumor signal was used for the large tumor
burden setting and median relative tumor signal in the
small tumor burden setting. Relative tumor signal is the
ratio of tumor signal at a specific time point compared
to just before virus inoculation.
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mice brains
Dissected brains were fixed in 10% neutral buffered forma-
lin over night, embedded in paraffin, and 5 μm sections
were cut. After deparaffinization, rehydration and antigen
retrieval was performed with citrate buffer. A custom
made rabbit antibody targeting the A27L structural pro-
tein of VACV (GenScript) was used for VACV detec-
tion in sections as described in Frentzen et al. [34].
Successive sections were stained for BMP-4 using a
mouse BMP-4 antibody (Cell Signalling). As a second-
ary antibody an HRP-conjugated anti-mouse (Vector
Laboratories) was used. Detection was performed using















Figure 1 VACV expressing BMP-4 facilitates differentiation of GBM CS
GLV-1h189 is the parental virus with insertions of a cDNA encoding a Renil
J2R (thymidine kinase) locus and a turboRFP (tRFP) cDNA in the A56R locus
replace the lacZ cDNA. The promoters are indicated in front of the boxes r
two viruses. Appearance of differentiated, adherent cells is evident upon G
GLV-1h189 infection (top right) at 9 dpi (Magnification 4X). C) BMP-4 gener
from GLV-1h285-infected spheroids (glowing green or red) differentiates th
(Magnification 10X).DAB Peroxidase substrate (Vector Laboratories) and sec-
tions were counterstained with Hematoxylin.
Statistical analyses
Statistical analyses of mice survival was assessed using the
log-rank test. A P value of less than 0.05 was considered
statistically significant.
Results
VACV mediated BMP-4 expression in GBM CSC cultures
facilitates differentiation and generates a bystander effect
GLV-1h189 is the parental VACV that has three inser-
tions, Renilla luciferase-GFP fusion cDNA in the F14.5 L








Cs. A) Schematic representation of the two viruses used in the study.
la luciferase and GFP fusion in the F14.5 L locus, a lac Z cDNA in the
. To construct GLV-1h285, a cDNA encoding BMP-4 was used to
epresenting the cDNAs. B) Infection of GBM CSC spheroids with the
LV-1h285 infection (bottom left) whereas spheroids remain intact upon
ated by GLV-1h285 has a distinct bystander effect. BMP-4 produced
e neighboring spheroids resulting in adherent cell clusters at 9 dpi
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GLV-1h189 was modified to introduce the cDNA of
BMP-4 into the TK locus. Expression of BMP-4 was con-
firmed by western blotting in both CV-1 cells and GBM
CSCs (data not shown). Upon infecting GBM CSC line
010627 (hereafter called GBM CSCs) with GLV-1h189 at
an MOI below 1, an average of 30-50% of the culture
was found to be infected by VACV, based on GFP or tRFP
expression (Figure 2A). Interestingly, a larger proportion
of cells were infected at similar MOIs with the virus
expressing BMP-4. An intact spheroid architecture was
observed for the uninfected cells as well as for cultures
infected with GLV-1h189 at all MOIs (Figure 1B, upper
panels). However, at an MOI of 0.25, GLV-1h285-infected
cultures showed a distinct disruption of the spheroid
structures of the GBM CSCs. From a central spheroid-like
structure, cells with an adherent morphology, indicativeGLV-1h189 MOI 0.25















Figure 2 Purified BMP-4 facilitates enhanced replication of GLV-1h18
(top panels) or presence (lower panels) of BMP-4 at 9 dpi. In the presence
clusters that are either infected or have a differentiated appearance. (Magn
as indicated by RLuc expression (relative light units, RLUs) at 9 dpi. GLV-1h1
ranged from approximately 4–50 fold higher compared to GBM CSCs infec
only, uninfected background control.of a differentiated phenotype, emerged (Figure 1B). At a
higher MOI of 0.5, a similar differentiated phenotype
was evident but with fewer cells in the culture possibly
due to loss of cells due to greater oncolytic activity of
VACV in differentiated cells (Figure 1B). Interestingly,
the adherent cell phenotype was prominent in spheroids
that were not actually infected themselves, but close to
neighboring infected spheroids, as indicated by GFP and
tRFP expression (Figure 1C). Since BMP-4 is a secreted
protein this observation is likely due to a bystander
effect of protein secretion from spheroids initially infected
with GLV-1h285. To further confirm that the morpho-
logical microscopic changes were indeed due to differen-
tiation, the expression of glial fibrillary acid protein (GFAP)
was monitored. GFAP expression is a well documented
marker for GBM stem cell differentiation into astrocytes
in response to exposure to BMP [19]. ImmunofluorescenceGLV-1h189 MOI 0.5





GLV-1h189 + 100 ng/mL
BMP-4
9 in GBM CSCs. A) GLV-1h189 infection of GBM CSCs in the absence
of BMP-4 the majority of the spheroids are broken down into cell
ification 4X). B) BMP-4 enhances replication of GLV-1h189 in GBM CSCs
89 in the presence of BMP-4 showed heightened replication that
ted with GLV-1h189 alone at MOIs less than 2. An MOI of 0 is cells
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heightened level of GFAP expression upon GLV-1h285
infection of GBM CSCs compared to that of GLV-1h189
(data not shown). To confirm that the differentiation
phenotype was in fact due to BMP-4 generated from
GLV-1h285, an infection of GBM CSCs was carried out
using GLV-1h189 in the presence of 100 ng/mL of recom-
binant BMP-4. As can be seen in Figure 2A GLV-1h189
infection alone resulted in infection of a small pro-
portion of spheroids with no change in the spheroid
architecture. However, in the presence of BMP-4, the
spheroid like architecture of the GBM CSCs was signifi-
cantly disrupted, with flat adherent cells emanating from
the spheroids. Both the remaining spheroid cells and ad-
herent cells were infected with GLV-1h189, as demon-
















































Figure 3 VACV expressing BMP-4 facilitates growth inhibition by highe
were used to infect the GBM CSCs at different MOIs and replication measured
observed for GLV-1h285 compared to GLV-1h189, especially at the lower MOI
from infections of the GBM CSCs 010627 (0627) and U87s with both viruses c
titer was obtained for GLV-1h285 compared to GLV-1h189 for the CSC line, bu
line. B) Growth inhibition assays for GLV-1h189 and GLV-1h285 viruses in the
of growth inhibition was observed for GLV-1h285 compared to GLV-1h189 in
observed for U87s for both viruses. C) Growth inhibition in the GBM CSCs upo
left and 9 dpi on right). Growth inhibition decreased at 9 dpi in case of GLV-1
escaped infection. However, this escape is not observed in case of GLV-1h285respectively. Furthermore, visual inspection of the wells
infected with GLV-1h189 in the presence of BMP-4 indi-
cated greater tRFP signals compared to wells infected with
GLV-1h189 alone at similar MOIs. The RLuc expression
from the cDNA introduced in the F14.5 L locus of VACV
has been validated as a marker for VACV replication using
the VACV maturation inhibitor, ST-246. This inhibitor
prevents infectious VACV particle formation. RLuc signal
decreased in an ST-246 dose dependent manner upon
infection of U-87s cells with GLV-1h189 (data not shown).
Therefore quantitative evaluation of RLuc expression,
from the wells infected with GLV-1h189 plus BMP-4 indi-
cated a significant increase in viral replication (Figure 2B).
This increase in expression was particularly obvious at













































0.25 0.5 1 2
1h285
1h189
r levels of replication in GBM CSCs. A) GLV-1h189 and GLV-1h285
by RLuc expression (RLUs, left panel). Higher levels of replication were
s. An MOI of 0 is cells only, uninfected background control. Plaque assays
onfirmed the RLuc expression data (Figure 3A, right panel). A higher viral
t GLV-1h285 did not replicate to a higher titer in case of the U87s cell
U87s cell line (left) and the GBM CSCs 010627 (0627, right). A higher level
the GBM CSCs. However, similar levels of growth inhibition were
n infection with GLV-1h189 and GLV-1h285 at two time points (6 dpi on







Fold less of GLV-1h 
285 to achieve same
inhibition
050509 0.0178 0.009 2.07
010627 2.738 0.505 5.42
020913 1.292 0.177 7.30
040622 0.155 0.007 22.14
071127 0.139 0.035 3.97
090310 1.179 0.525 2.25
040325 0.2 0.139 1.44
090529 0.000428 0.000001 525.06































Fold less of GLV-1h 
285 to achieve same
inhibition
U373 1.49 0.85 1.75
U251 0.49 1.40 0.35
C
Figure 4 BMP-4 reduces the amount of VACV needed to achieve
growth inhibition in GBM CSCs and has no role in VACV oncolytic
activity in glioma serum-grown cell lines. A) representative growth
inhibition curves of GBM CSC line 040622 upon infection with the pair
of VACVs, GLV-1h189 and GLV-1h285. The EC50 value for each virus is
indicated by a black arrow intercepting the X-axis and the difference
between the EC50 values is shown by the broad double headed arrow.
B) EC50 values for GLV-1h189 and GLV-1h285 upon infection of 9 GBM
CSC lines. The fold difference between the EC50 values of GLV-1h189
and GLV-1h285 viruses are in the column on the far right. C) EC50 values
to indicate growth inhibition kinetics by GLV-1h189 and GLV-1h285 in
two serum-grown glioma cell lines, U373 and U251 adapted to grow
under stem cell conditions.
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inhibition due to heightened specific replication in
GBM CSCs
To determine whether the increase in VACV replication
facilitated by purified BMP-4 also occurs when the pro-
tein is expressed from the virus itself, GLV-1h285 was
used to infect GBM CSCs at various MOIs (Figure 3A,
left panel) and RLuc expression determined. As expected,
substantially higher RLuc expression was observed for
GLV-1h285 compared to GLV-1h189 infections, espe-
cially at lower MOIs of 0.25 and 0.5. Furthermore, when
the GBM CSCs and a serum-grown glioma cell line adapted
to stem cell conditions, U87s, were infected at an MOI
of 0.25, a three-fold higher viral titer was obtained from
cultures infected with GLV-1h285 compared to those
with GLV-1h189 (Figure 3A, right panel). However, for
U87s, the production of progeny virus from GLV-1h285
appeared to be slightly reduced compared to GLV-1h189,
though close to the range of variability of the assay.
In growth inhibition assays, which examine the viability
of cells upon viral infection and expression of BMP-4, the
U87s cultures exhibited similar growth inhibition after
infection by GLV-1h285 or GLV-1h189 (Figure 3B, left
panel). However, in the case of GBM CSCs, GLV-1h285
showed accentuated growth inhibition compared to GLV-1
h189 (Figure 3B, right panel) corroborating the higher
levels of replication of GLV-1h285 in the GBM stem cell
cultures.
To examine the growth inhibition kinetics further in
GBM CSCs, an early time point of 6 dpi was included when
GBM CSCs were infected with GLV-1h189 and GLV-1h285
at different MOIs (Figure 3C). Differences between the
two viruses in growth inhibition were obvious for the
early time point with greater inhibition for GLV-1h285,
especially at lower MOIs. At the 9 dpi time point, the
differences became very pronounced, again especially
at lower MOIs.
Broad spectrum activity and reduced BMP VACV
requirement for cytotoxicity across several patient-derived
GBM CSC lines
The activity of GLV-1h285 was tested in eight additional
patient-derived GBM CSC lines in growth inhibition as-
says in parallel with GLV-1h189. As shown in Figure 4A,
the EC50 values for GLV-1h189 and GLV-1h285, upon
infecting the representative GBM CSC line 040622, were
quite different with a substantially larger amount (22.14
fold) of GLV-1h189 required for the same degree of
growth inhibition as GLV-1h285, suggesting that BMP-4
production might have a general role in facilitating
VACV replication in GBM patient samples. Similar ten-
dencies were observed for the majority of the cell lines
except 040325 and 061205 (Figure 4B), possibly due to a
higher differentiation status of the patient sample fromwhich the cell lines were derived. Further evidence for
excluding a role of BMP-4-mediated growth inhibition
in differentiated cells in the context of VACV infection
came from testing more differentiated cancer cell lines
grown in the presence of serum. Two additional serum-
grown glioma lines, U373 and U251 were tested with
the GLV-1h285 and GLV-1h189 virus pair. Both cell lines
showed very similar growth inhibition kinetics for both
viruses as indicated by similar EC50 values (Figure 4C).
Intracranial implantation of GBM CSCs forms authentic
GBM in brains of immunocompromised mice
In order to develop an orthotopic animal model using the
GBM CSCs and to facilitate real time tumor growth meas-
urement, a firefly luciferase (FLuc) cDNA was introduced
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virus transduction [20]. This FLuc-expressing variant of
the GBM CSC line, 010627 hereafter called GBM FLuc
CSCs was stereotactically introduced at specific coordi-
nates in the brains of nude mice. To distinguish tumor
growth of the GBM CSCs in mice from other conven-
tional serum-grown glioma cells lines, the U87 glioma
line was transfected with a plasmid containing the cDNA
for FLuc to develop a stable U87 variant capable of ex-
pressing firefly luciferase, U87 FLuc. U87 FLuc cells were
implanted intracranially similar to the GBM FLuc CSCs.
Two to three weeks after implantation an FLuc signal
could be detected in the brain for both cell lines upon
administration of luciferin. However, as first reported by
Galli et al. [4], the pattern of tumor growth was distinctly
different for the two cell cultures. The GBM FLuc CSCs
start to spread from the site of implantation at right side
of the cerebrum to the left side of the cerebrum, via the
corpus callosum, at about 42 days post implantation
(Figure 5, top). This spread is considered a hallmark fea-
ture of GBM in patients [35]. Furthermore, the spread
was highly invasive with complete infiltration of the
cerebrum occurring within the next two weeks, ultim-
ately appearing like a classical diffused GBM (Figure 5A,
day 55, [35]). In contrast, the U87 FLuc cells upon im-
plantation developed a luciferase signal only on the right






Figure 5 The GBM CSCs generate an invasive and infiltrative pattern
glioblastoma in patients. A) Real time imaging of GBM 010627 FLuc CSC
immunocompromised mice. The invasive migratory pattern of cells origina
observed as luminescence (blue) eventually spreads throughout the brain (
implanted in the brains of immunocompromised mice. As opposed to the
cell line (luminescence, blue) remained localized around the site of implan
to enlarge only on that side of the brain (day 49). The green color is a false
generate adequate contrast with the luminescence (blue).implantation). The signal grew to some extent over time,
but remained localized to the right side of the brain unlike
the infiltrative tumor growth observed in GBM patients.
By 49 days post implantation the majority of the animals
expired mainly due to the build up of intracranial pressure
on one side of the cranium.
VACV mediated BMP-4 expression results in rapid tumor
regression and improved survival in
immunocompromised mice (low tumor burden)
In order to test the activity of the BMP-4 VACV in the
GBM CSC FLuc animal model, GLV-1h285 and GLV-1h189
were injected at the same coordinates as the tumor cells
two weeks after implantation in a low tumor burden set-
ting. BMP-4 production could be detected in GBM CSC
implants in mice brains upon GLV-1h285 infection by
immunohistochemistry analysis using a BMP-4 specific
antibody (Figure 6B). The BMP-4 expression was found to
coincide with detection of VACV proteins in these mice
brains by using an anti VACV structural protein antibody
by immunohistochemistry analyses (Figure 6A).
Tumor growth was evaluated in real time by measur-
ing and quantitating FLuc expression on a weekly basis
(Figure 7). The untreated tumors grew rapidly and in-
creased in size approximately 670 fold (Figure 7A). In
mice inoculated with GLV-1h189 a significant increase
in tumor size of up to 175 fold was observed at 51 dpiDay 49y 42
y 47 Day 55
0627 FLuc 
ma FLuc
of tumor growth in nude mouse brains reminiscent of
line (GBM CSC 0627 FLuc) after being implanted in the brains of
ting from the site of the GBM CSC implantation (day 42) that can be
day 55). B) Real time imaging of U87 FLuc cell line after being
signal pattern from the GBM CSC line, the signal from the U87FLuc
tation in the right part of the cerebrum (day 36) and the tumor tended





Figure 6 Colocalization of VACV and BMP-4 staining in brains
of GBM xenografts. Successive paraffin-embedded tumor sections
of a GLV-1h285 infected mouse brain implanted with GBM CSCs
analyzed by immunohistochemistry, 98 days post injection of the
virus. A) Detection of VACV structural protein, A27L for identification
of areas of tumors infected with VACV. B) Detection of BMP-4
expression generated by GLV-1h285. Identification of both proteins
in overlapping regions of the tumor is indicative of active BMP-4







































Figure 7 Rapid and superior tumor regression in GBM CSC
implanted mice by BMP-4 VACV translates into improved survival
(low tumor burden). A) Relative tumor signals as measured by
intracranial FLuc expression from GBM FLuc CSCs in mice followed by
inoculation of GLV-1h189 and GLV-1h285 at two weeks post-
implantation. The GLV-1h285-colonized tumors remained at the
original size of the point of virus inoculation up to 51 dpi. The GLV-1
h189-colonized tumors were controlled until 37 dpi, followed by a
rapid increase in tumor size. The untreated controls showed rapid,
uncontrolled tumor expansion. B) Survival of the implanted and
inoculated mice as shown by Kaplan-Meier survival curves. All mice in
the untreated group died by day 60. In the GLV-1h189 group, 60% of
the mice expired around 80 dpi. However, in the GLV-1h285 group, all
mice were alive until 91 dpi. * Indicates P < 0.05 for the GLV-1h285
group when compared with the untreated or the GLV-1h189 groups.
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untreated control (Figure 7A). In contrast, intracranial
administration of GLV-1h285 controlled the tumor size
to around or below the initial size, even up to 51 dpi
(Figure 7A).
The tumor regression data was found to correspond
with survival for the three groups of mice. By 60 dpi, all
mice in the untreated control group had either died or
had to be euthanized (Figure 7B). Sixty percent of the
mice inoculated with GLV-1h189 started to lose weight
by 60 dpi and expired soon after (Figure 7B). However,
in the GLV-1h285 treated group, all mice were alive
until 91 dpi (Figure 7B), indicating a significant survival
advantage imparted by viral BMP-4 expression.
VACV-mediated BMP-4 expression drastically delays
tumor progression and improves survival in
immunocompromised mice (high tumor burden)
The efficacy of GLV-1h285 in tumors initiated by GBM
FLuc CSCs was also assessed in a higher tumor burden
setting. The tumors were allowed to grow for 7 weeks
instead of 2 weeks and the viruses were inoculated sub-
sequently. Comparison of the tumor signals after inocu-
lation of GLV-1h189 or GLV-1h285 virus revealed adelay in tumor signal peak for GLV-1h285 compared to
GLV-1h189 (Figure 8A). Furthermore, a recurrence of
tumor signal was observed only for GLV-1h189 inocu-
lation at 62 dpi onwards, with rapid tumor progression
in 80% of the surviving mice. Interestingly, when the
survival data was plotted under the tumor signal data
(Figure 8B), GLV-1h189 inoculated mice started to
expire around 24 dpi with an increase in tumor signal.
Another steep decline in survivability was observed at
the point where recurrence of tumor signal occurred
at 62 dpi. In case of the GLV-1h285 inoculated group,



















































Figure 8 BMP-4 VACV controls tumor growth and improves survival in mice implanted with GBM CSCs (high tumor burden). A) Median
tumor signals as measured by intracranial FLuc expression from GBM FLuc CSC line implanted in mice followed by inoculation of GLV-1h189
or GLV-1h285 seven weeks post implantation. GLV-1h189-colonized tumors peaked at 26 dpi compared to GLV-1h285 which peaked at 39 dpi. In
GLV-1h189-colonized tumors furthermore, at 62 dpi a signal increase due to recurrence of the originally recessed tumor was observed.
B) Kaplan-Meier survival curve for the experiment described in A. All animals in the untreated group died around 42 dpi. A drop in survival was
observed for both treated groups of animals albeit later for the GLV-1h285 group following the trend in tumor signal peaks. However, the
survival advantage for the GLV-1h285 group was superior with almost 60% of the treated animals surviving compared to only 10% of the
animals surviving in the GLV-1h189 group. C) Representative whole brains from the mice in the untreated group (top left), GLV-1h189 group
(top right) and GLV-1h285 group (bottom). The untreated brain showed an enlarged right half of the cerebrum where severe necrosis and
hematoma were observed. The brain from the only surviving mouse in the GLV-1h189 group and representative brains from the GLV-1h285
group show healthy brain tissue. * Indicates P < 0.05 for the GLV-1h285 group compared with untreated or the GLV-1h189 groups. ** Indicates
P < 0.05 for the GLV-1h189 group compared with the untreated group.
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GLV-1h189 inoculated group, with almost 60% of the
mice surviving.
Upon euthanasia or termination of the study, the
brains of the animals were harvested for examination.
Brains from the uninfected group animals showed a highdegree of necrosis and hematoma, especially on the
right side of the brain where the cells were implanted
(Figure 8C top left). Brains from the majority of the
GLV-1h285 inoculated mice (Figure 8C bottom) showed
substantial improvement in gross morphology compared
to the uninfected mice. The few mice that survived after
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at the site of implantation (Figure 8C top right).
Discussion
Functional activity of oncolytic viruses is considered to
be immune to mechanisms attributed to generate cancer
resistance against chemotherapeutic agents and radiation
modalities that are considered to reside in CSCs [36].
However, there is a lack of precedence for robust and
validated CSC systems to be tested extensively with
oncolytic viruses, especially with oncolytic VACVs. The data
presented in this study demonstrates the feasibility of
designing a VACV that expresses a stem cell differenti-
ation agent, BMP-4 to successfully target infected and
non infected undifferentiated GBM CSCs. The resulting
effect of a BMP-4 expressing VACV infection causes an
enhanced growth inhibition of GBM stem cells in vitro
and substantial tumor regression in mice compared to
the parental, non-BMP-4 carrying VACV.
BMP-4, a member of the TGF-β super family of secreted
proteins has been shown to have potential applications in
treating GBM and colon cancer [19,30]. However, for
making this possible as a treatment modality in patients
extensive efforts are required for protein purification.
Furthermore, the delivery to the site of action is quite
challenging with the protein required to be immobilized
on glass spheres or delivered via convection enhanced
delivery [19,37,38]. Therefore, expressing BMP payloads
from a VACV platform has significant advantages in terms
of protein production and delivery in the tumor. In this
study we have designed a VACV that successfully ex-
presses BMP-4 and tested this virus in previously validated
GBM CSC in vitro and animal model systems [4,19].
Quite surprisingly we observed an increase in replica-
tion of the BMP-4 VACV in GBM CSC cultures compared
to the parental virus and it was found to be specific to the
GBM CSC cultures compared to other serum-grown gli-
oma cell cultures (Figures 3 and 4). This is potentially
attributed to enhanced second and possibly third round
infections facilitated by differentiation by BMP-4 action
on the GBM stem cells. Furthermore, the growth inhib-
ition by the BMP-4 virus was substantially greater in
GBM CSC cultures compared to the parental virus
(Figure 3C). BMP-4 specifically retards GBM cancer
stem cell growth [19]. The increase in VACV replication
of a CSC culture in the presence of BMP-4 could be due
to the ability of the virus to better infect cells that have
undergone differentiation. This could result in reduced
escape of infection for progeny cells. Hints towards this
mechanism of heightened infection and subsequent growth
inhibition in the presence of BMP-4 came from the ob-
servation that the parental, non-BMP-4 virus infection
resulted in reduced growth inhibition at the later time
point of day 9 compared to day 6, possibly due to cellsthat had escaped infection contributing to greater pro-
liferation and reduced growth inhibition (Figure 3C).
This phenomenon may simulate the tumor recurrence
that is observed in the brains of mice (Figure 8A) and in
GBM patients undergoing treatment. However, in the
presence of BMP-4 the growth inhibition even increases
a little from 6 dpi to 9 dpi for GLV-1h285.
It has been considered that CSCs display potential re-
sistance to infection (replication) by oncolytic viruses
engineered for an attenuated phenotype. This was con-
firmed by our observation that the parental virus infects
only 30-50% of the GBM CSC cultures. Elevated inter-
feron levels due to an innate immunity response in CSCs
relative to bulk tumor cells is considered to decrease
sensitivity to oncolytic virus infection [36]. It would be
interesting to determine whether differentiation facili-
tates lowering of innate immunity and whether that
causes an increase in VACV replication in the presence
of BMP-4. Additionally the BMP-4 stimulated replication
of VACV was more prominent at lower MOIs compared
to the parental virus (Figure 3A). This was possibly due to
the presence of more viable cells facilitating greater
second and third round infections by the virus that ex-
presses BMP-4 and reduced capability of the parental
virus to generate substantial infection of the culture at
lower MOIs. At higher MOIs for both viruses there
was greater parity in terms of replication since fewer cells
escape infection. Therefore, differentiation by BMP-4 ap-
pears to facilitate infection which can be achieved by using
more virus. This higher level of replication for the BMP-4
producing virus, GLV-1h285 results in a lower EC50 value
indicating the need for lesser amounts of GLV-1h285 to
generate the same level of inhibition as the parental virus,
GLV-1h189. Furthermore, it appears that the growth in-
hibition due to GLV-1h189 was by oncolytic activity alone
and that of GLV-1h285 due to oncolytic activity by basic
VACV infection, growth inhibition by BMP-4 protein and
oncolytic activity facilitated by the differentiation carried
out by the BMP-4 payload. Evidence for action of the virus
generated BMP-4 protein alone comes from observing
micrographs where we observed a distinct bystander
effect of the secreted protein on GBM CSC spheroids
that show a differentiated morphology without being
infected (Figure 1C). As was observed in our earlier stud-
ies with pure BMP-4 protein and growth retardation of
GBM CSC initiated tumors due to differentiation, the
differentiated GBM CSCs show significantly reduced
proliferation due to decline in number of cell divisions.
Interestingly, we observe that the differentiated cells are
a better substrate for VACV infection. Whether this
happens at the entry step or other stages of the virus life
cycle remains to be determined and will be the objective
of future studies. However, the three mechanisms of ac-
tion: basic VACV oncolytic activity of initially infected
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these that results in differentiation and facilitation of
second and third round infections of the differentiated
GBM CSCs resulting in greater oncolytic activity causes
significant cellular growth inhibition that translates into
tumor growth inhibition in brains of mice implanted
with the GBM CSCs.
In case of GBM CSC lines 040325 and 061205, the
EC50s for GLV-1h285 and GLV-1h189 are very similar,
possibly due to a higher level of differentiation of the
tumor tissue these lines were derived from. Indeed, in
response to exposure to recombinant BMP-4, the 061205
cell line shows reduced growth inhibition compared to
other cell lines (Vescovi and Duggal, unpublished). How-
ever, this seems to be the exception than the rule among
the nine primary cell lines tested, but also indicating the
important utility of the basic oncolytic activity of the
VACV platform for tumor growth inhibition. Similarly in
case of the serum-grown glioma cell lines, U87, U251 and
U373, very small differences in growth inhibition were
observed between GLV-1h189 and GLV-1h285. As is
well documented, growing primary tumor samples
under serum conditions selects for a population of cells
with a more differentiated phenotype and a genetic makeup
different from the original tumor sample [39-41]. Hence,
it is not surprising to see lack of superior growth inhib-
ition for the BMP-4 producing virus in differentiated
glioma lines since BMP-4 is believed to target undiffer-
entiated, stem cell-like cells. Furthermore, seeing a pref-
erence for the BMP-4 virus to replicate and rapidly
carry out second and later round infections in the GBM
CSC cells is further reassuring as to an undifferentiated,
stem cell-like population comprising a significant part
of the culture that has a genetic makeup similar to the
original tumor [40].
In this study we confirmed in animal xenograft models
that the GBM CSCs reproduce the disease much more
closely as it occurs in patients [4]. Compared to a represen-
tative serum-grown glioma cell line, U87 which remained
restricted to one side of the brain, the GBM CSCs migrated
to the contralateral cerebral hemisphere possibly via the
corpus callosum, a hallmark migratory pattern observed in
GBM patients (Figure 5) [4,35]. Furthermore, as is the case
with GBM patients the GBM CSC tumors were found to
be highly vascular compared to the U87 generated tumors
[42,43]. Working with such GBM CSC models could
possibly facilitate greater translation of preclinical data
in the clinic.
In the GBM CSC animal models we observed a benefit
in treating the tumor with the BMP-4 virus without any
overt side effects in two different tumor burden settings.
Under a low tumor burden setting, the BMP-4 virus caused
tumor regression and kept the tumor in check to below
the signal when the tumor was first infected up to 51 dpi(Figure 7A). This resulted in significant survival advantage
compared to the untreated control group and the paren-
tal virus treated group. At a higher tumor burden, the
BMP-4 virus delayed tumor growth compared to the
parental virus (Figure 8A). Interestingly, the tumor signal
of the parental virus treated group showed a rebound after
being suppressed from 33 dpi to 62 dpi, a signature event
in GBM commonly seen after treatment [44]. However,
we did not see a tumor rebound in the BMP-4 virus
treated group, supporting the hypothesis that BMP-4
production could disrupt cancer stem cell propagation
in GBM.
With CSCs comprising a small population of the tumor
there is a concern that the effect of CSC specific inhibitors
might not be visible in animal models. Furthermore, this
could be reflected in the clinic where the outcome might
not register as suitable patient response in terms of
tumor growth inhibition as evaluated by classical Re-
sponse Evaluation Criteria In Solid Tumors (RECIST).
Oncolytic viruses on the other hand, with suitable pay-
loads (such as BMPs) to target CSCs could have the
ability to register suitable RECIST end points due to
their ability to target CSCs, differentiated CSC progeny
upon exposure to BMPs and bulk tumor cells. This could
consequently increase the chances of observing suitable
tumor regression. Additionally, testing oncolytic viruses
carrying CSC targeting payloads in diseases such as glio-
blastoma where the tumor is comprised of a larger pro-
portion of CSCs might have more noticeable effects in a
preclinical setting as was observed in the current study.
Our study gives the first glimpse of BMP-4 as an effica-
cious oncolytic virus payload for treating GBM with few
side effects. The intracranial delivery of the BMP-4
VACV could possibly be implemented in the clinic in an
adjuvant setting similar to what has been done with
carmustine wafers after surgical resection [45]. The data
presented here also suggests further evaluation of BMPs
in combination with other payloads in the context of
the VACV platform with a near term goal of testing in
the clinic.
Conclusions
We have used clinically relevant models of GBM using
primary CSC-enriched cell preparations to test the activity
of a VACV that expresses BMP-4. During this process, we
have further confirmed the utility of these primary CSC-
enriched systems for drug discovery and introduced real
time imaging to monitor effects of the BMP-4 VACV on
tumor growth. The BMP-4 VACV was found to have
greater levels of replication in these GBM CSC systems
compared to the parental virus. This was attributed
directly to the expression of BMP-4 which facilitates
replication by differentiating CSCs that can serve as a
better host for VACV infection. The heightened level
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tumor growth inhibition and survival of mice implanted
with GBM CSCs. We believe the data in this article pro-
vides a foundation for further evaluation of BMP-4 in the
context of VACV replication in combination with other
treatments in cancer indications such as GBM in the clinic
in the near future.
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